4
Changes in Ownership
LENZ Therapeutics, Inc. Filed Acc 0000899243-21-027015
CHIEF OPERATING OFFICER acquired 8,126 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stultz Katherine V CHIEF OPERATING OFFICER | 2021-06-29 | Conversion | +8,126 | 216,020 | D: show line 1 in the form |
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stultz Katherine V CHIEF OPERATING OFFICER | 2021-01-13 | Grant or award · Stock Option (right to buy) | +99,753 | 99,753 | D: show line 2 in the form | ||
| Stultz Katherine V CHIEF OPERATING OFFICER | 2021-03-11 | Grant or award · Series B Preferred Stock | +19,763 | $5.06 | $100,001 | 19,763 | D: show line 3 in the form |
| Stultz Katherine V CHIEF OPERATING OFFICER | 2021-03-17 | Grant or award · Stock Option (right to buy) | +209,846 | 209,846 | D: show line 4 in the form | ||
| Stultz Katherine V CHIEF OPERATING OFFICER | 2021-03-17 | Grant or award · Stock Option (right to buy) | +89,934 | 89,934 | D: show line 5 in the form | ||
| Stultz Katherine V CHIEF OPERATING OFFICER | 2021-06-29 | Conversion · Series B Preferred Stock | −19,763 | 0 | D: show line 6 in the form |
Loading xslF345X03/doc4.xml…